PharmaCyte Biotech | 8-K:重大事件
PharmaCyte Biotech | ARS:年度报告
PharmaCyte Biotech | DEF 14A:股东委托书决议
PharmaCyte Biotech | 10-Q:季度报表
PharmaCyte Biotech | SC 13G:超过5%持股股东披露文件-Ayrton Capital LLC(9.9%),Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B(9.9%)等
PharmaCyte Biotech | SC 13G/A:超过5%持股股东披露文件(修正)-Mitchell P. Kopin(9.99%),Daniel B. Asher(9.99%)等
PharmaCyte Biotech:2024财年二季报
PharmaCyte Biotech | 3:首次持股声明-股东 PharmaCyte Biotech, Inc.
PharmaCyte Biotech | 8-K:重大事件
PharmaCyte Biotech | 4:持股变动声明-董事 WEINSTEIN ROBERT
PharmaCyte Biotech | 4:持股变动声明-董事 WALKER WAYNE REMELL
PharmaCyte Biotech | 4:持股变动声明-首席财务官 Trujillo Carlos
PharmaCyte Biotech | 4:持股变动声明-高管 Silverman Joshua
PharmaCyte Biotech | 4:持股变动声明-董事 SCHECHTER JONATHAN
PharmaCyte Biotech | 4:持股变动声明-董事 Abecassis Michael M
PharmaCyte Biotech | SC 13D:超过5%持股股东披露文件-PharmaCyte Biotech, Inc.(37.0%)
PharmaCyte Biotech | 8-K:重大事件
PharmaCyte Biotech | 8-K:重大事件
PharmaCyte Biotech | EFFECT:其他
PharmaCyte Biotech | CORRESP:信函
暂无数据